<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02264015</url>
  </required_header>
  <id_info>
    <org_study_id>503.204</org_study_id>
    <nct_id>NCT02264015</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, to Healthy Male and Female Volunteers, With an Intra-individual Comparison to Moxifloxacin in a Subset of Volunteers</brief_title>
  <official_title>Pharmacodynamic Effects, Safety and Tolerability of 2 mg and 5 mg Cilobradine, Administered p.o. Once Daily Over 14 Days to Healthy Male and Female Volunteers in a Randomised, Placebo-controlled, Double Blind Study, With an Open-label Uncontrolled Intra-individual Comparison to 400 mg Moxifloxacin Single Dose in a Subset of Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Incidence of visual phenomena, heart rate at rest, safety (with particular emphasis on QT
      analysis of ECGs), and pharmacokinetic parameters
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <primary_completion_date type="Actual">May 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of visual phenomena</measure>
    <time_frame>Up to 12 days after last scheduled study day</time_frame>
    <description>Reported as adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in heart rate at rest</measure>
    <time_frame>Pre dose, up to 12 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator assessed tolerability on a 4 point scale</measure>
    <time_frame>Up to 12 days after last scheduled study day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal findings in physical examination</measure>
    <time_frame>Up to 12 days after last scheduled study day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in vital signs</measure>
    <time_frame>Up to 12 days after last scheduled study day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to 12 days after last scheduled study day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of visual phenomena on a special questionnaire</measure>
    <time_frame>Up to 12 days after last scheduled study day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal changes in clinical laboratory parameters</measure>
    <time_frame>Up to 12 days after last scheduled study day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal findings in electrocardiogram (ECG)</measure>
    <time_frame>Up to 12 days after last scheduled study day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma from zero time to 24 hours (AUC0-24)</measure>
    <time_frame>Up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration following the first dose (Cmax)</measure>
    <time_frame>Up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from first dose to the maximum plasma concentration (tmax)</measure>
    <time_frame>Up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2)</measure>
    <time_frame>Up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time of the analyte in the body after oral administration (MRTpo)</measure>
    <time_frame>Up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance of the analyte in plasma following extravascular administration (CL/F)</measure>
    <time_frame>Up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during the terminal phase λz following extravascular administration (Vz/F)</measure>
    <time_frame>Up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cilobradine low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cilobradine high</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilobradine, low, film-coated tablets</intervention_name>
    <arm_group_label>Cilobradine low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilobradine, high, film-coated tablets</intervention_name>
    <arm_group_label>Cilobradine high</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, film-coated tablets</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin, film-coated tablets</intervention_name>
    <arm_group_label>Moxifloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males and females according to the following criteria:

             Based upon a complete medical history, including the physical examination, vital signs
             (blood pressure (BP), pulse rate (PR)), 12-lead Electrocardiogram (ECG), clinical
             laboratory tests

             1.1 No finding deviating from normal and of clinical relevance

             1.2 No evidence of a clinically relevant concomitant disease

          2. Age ≥21 and Age ≤55 years

          3. BMI ≥18.5 and BMI &lt; 30 kg/m2 (Body Mass Index)

          4. Resting Heart rate (HR) (after 10 min. in the supine position) of equal or more than
             60 bpm

          5. Females: post-menopausal or those who have had a hysterectomy (plus a negative
             pregnancy test)

          6. Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice (GCP) and the local legislation

        Exclusion Criteria:

          1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological, ophthalmological, or hormonal disorders

          2. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          3. History of relevant orthostatic hypotension, fainting spells or blackouts

          4. Chronic or relevant acute infections

          5. History of allergy/hypersensitivity (including drug allergy) which is deemed relevant
             to the trial as judged by the investigator

          6. Intake of drugs with a long half-life (&gt;24 hours) within at least one month or less
             than 10 half-lives of the respective drug prior to administration or during the trial

          7. Use of drugs which might reasonably influence the results of the trial based on the
             knowledge at the time of protocol preparation within 10 days prior to administration
             or during the trial

          8. Participation in another trial with an investigational drug within two months prior to
             administration or during the trial

          9. Smoker (more than 10 cigarettes or 3 cigars or 3 pipes/day)

         10. Inability to refrain from smoking on trial days

         11. Alcohol abuse

         12. Drug abuse

         13. Blood donation (more than 100 mL within four weeks prior to administration or during
             the trial)

         14. Excessive physical activities (within one week prior to administration or during the
             trial)

         15. Any laboratory value outside the reference range that is of clinical relevance.

             Exclusion criteria specific for this study:

         16. Subjects at increased risk for development of cardiac arrhythmia (e.g. family history
             of long QT syndrome or sudden cardiac death)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2014</study_first_submitted>
  <study_first_submitted_qc>October 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2014</study_first_posted>
  <last_update_submitted>October 13, 2014</last_update_submitted>
  <last_update_submitted_qc>October 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

